Skip to main content
60°
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Oncology Pharma Inc.
Oncology Pharma Conducting Interviews and Presentations with Investors to Pursue Next Steps to Forward The Development Process of Nanoemulsion Drug Delivery System
July 12, 2022
From
Oncology Pharma Inc.
Via
AccessWire
Tickers
ONPH
Oncology Pharma Conducting All The Preparations to Take Steps to Forward The Development Process of Nanoemulsion Drug Delivery System
June 29, 2022
From
Oncology Pharma Inc.
Via
AccessWire
Exposures
Product Safety
Tickers
ONPH
Oncology Pharma Announces: Initial Feasibility Study of the Nanoemulsion Drug Delivery System is Complete and Results Have Met the Threshold for Moving Forward To the Next Steps of Development
June 08, 2022
From
Oncology Pharma Inc.
Via
AccessWire
Tickers
ONPH
Oncology Pharma Advances Progress on Multiple Fronts Including Advanced Attention to Connect2Trials' Commercial Development
May 09, 2022
From
Oncology Pharma Inc.
Via
AccessWire
Tickers
ONPH
Oncology Pharma Completes Feasibility Phase of its Licensed Nanoemulsion Drug Delivery System to Treat Cancer
April 13, 2022
From
Oncology Pharma Inc.
Via
AccessWire
Tickers
ONPH
Oncology Pharma Reports on Progress with Ribera Solutions
March 02, 2022
From
Oncology Pharma Inc.
Via
AccessWire
Tickers
ONPH
Oncology Pharma Releases Further Feasibility Studies, Data and Capacities
February 23, 2022
From
Oncology Pharma Inc.
Via
AccessWire
Tickers
ONPH
Oncology Pharma Expands on Feasibility Studies and Data
February 17, 2022
From
Oncology Pharma Inc.
Via
AccessWire
Tickers
ONPH
Oncology Pharma, Inc. and Regen BioPharma, Inc. Announce Intent to Jointly Fast Track Development of Modified mRNA anti-Cancer Vaccine
February 14, 2022
From
Oncology Pharma Inc.
Via
AccessWire
Tickers
ONPH
RGBP
RGBPP
Oncology Pharma Gives Update on Technology, Formulation and Data Creation
February 08, 2022
From
Oncology Pharma Inc.
Via
AccessWire
Tickers
ONPH
Oncology Pharma's New Year Update
January 10, 2022
From
Oncology Pharma Inc.
Via
AccessWire
Tickers
ONPH
Oncology Pharma Meeting Towards Future Developments
December 17, 2021
From
Oncology Pharma Inc.
Via
AccessWire
Tickers
ONPH
Oncology Pharma Year End Review and Outlook
December 09, 2021
From
Oncology Pharma Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Tickers
ONPH
Oncology Pharma Research and Vision
November 30, 2021
From
Oncology Pharma Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Tickers
ONPH
Oncology Pharma Reveals Plans for Development of Lead Cancer Drug Candidate
November 08, 2021
From
Oncology Pharma Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Tickers
ONPH
Oncology Pharma, Inc. Gives Update on Ongoing Work and Progress
October 27, 2021
From
Oncology Pharma Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Tickers
ONPH
Oncology Pharma, Inc. Has Engaged a PCAOB Audit Firm Looking Towards Moving the Company Towards a Senior Listing
October 15, 2021
From
Oncology Pharma Inc.
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
Intellectual Property
Legal
Regulatory
Tickers
ONPH
Oncology Pharma, Inc. Update on PCAOB Audit Selection Process and License Agreement
October 12, 2021
From
Oncology Pharma Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Tickers
ONPH
Oncology Pharma, Inc. Has Received the Committed Funding to Perform All Necessary IND-Enabling Preclinical Work for Its First Lead Candidate, a Dactinomycin Nanoemulsion Drug Product
September 13, 2021
From
Oncology Pharma Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Tickers
ONPH
Oncology Pharma's Co-Development Agreement Pursues Strategic and Direct Objectives
August 23, 2021
From
Oncology Pharma Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Tickers
ONPH
Oncology Pharma, Inc. Executes Co-Development Agreement with NanoSmart Pharmaceuticals, Inc.
August 19, 2021
From
Oncology Pharma Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Tickers
ONPH
Oncology Pharma, Inc. To Move to Conducting Trials on Licensed IP
July 20, 2021
From
Oncology Pharma Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Tickers
ONPH
Oncology Pharma, Inc. is Entering Into the Next Phase of its Growth and Expansion Phase
June 30, 2021
From
Oncology Pharma Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Tickers
ONPH
Oncology Pharma, Inc. Eyes Collaboration with Patent Opportunities Amongst Its Licensed Intellectual Properties
June 15, 2021
From
Oncology Pharma Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Tickers
ONPH
Oncology Pharma and Ribera Solutions Release White Paper Regarding Patient Engagement and Retention Platform
June 09, 2021
From
Oncology Pharma Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Tickers
ONPH
Oncology Pharma, Inc. Is Pursuing the Development of Its Small Molecule Drug for the Treatment of Colon Cancer
May 18, 2021
From
Oncology Pharma Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Tickers
ONPH
Oncology Pharma, Inc. Has Submitted Its Initial Application to List the Company on the Capital Markets Tier of the NASDAQ Exchange
May 12, 2021
From
Oncology Pharma Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Tickers
ONPH
Oncology Pharma Enters into License Agreement for Small Molecules Intellectual Property for the Treatment of Colon Cancer
May 07, 2021
From
Oncology Pharma Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Tickers
ONPH
Oncology Pharma, Inc. Prepares Plan Toward Funding Development and Implementation of Ribera Solutions' Patient Engagement and Retention Platform
April 21, 2021
From
Oncology Pharma Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Tickers
ONPH
Oncology Pharma, Inc. Addresses Pancreatic Cancer, the Need for an Effective Therapy and the Potential of mRNA Technology
April 14, 2021
From
Oncology Pharma Inc.
Via
AccessWire
Topics
Death
Intellectual Property
Exposures
Death
Intellectual Property
Tickers
ONPH
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.